Lupin Limited Asset Resilience Ratio
Lupin Limited asset resilience ratio. Lupin Limited (LUPIN) has an Asset Resilience Ratio of 9.32% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read LUPIN current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Lupin Limited (2012–2026)
Asset resilience ratio of Lupin Limited from 2012 to 2026. This chart shows how Lupin Limited's Asset Resilience Ratio has changed over time. See Lupin Limited free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Lupin Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Lupin Limited asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 0% |
| Short-term Investments | Rs35.77 Billion | 9.32% |
| Total Liquid Assets | Rs35.77 Billion | 9.32% |
Asset Resilience Insights
- Limited Liquidity: Lupin Limited maintains only 9.32% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Lupin Limited Industry Peers by Asset Resilience Ratio
Compare Lupin Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL |
Drug Manufacturers - Specialty & Generic | 5.90% |
|
Zhejiang Medicine Co Ltd
SHG:600216 |
Drug Manufacturers - Specialty & Generic | 1.85% |
|
Hunan Warrant Pharmaceutical Co. Ltd. A
SHG:688799 |
Drug Manufacturers - Specialty & Generic | 0.40% |
|
Dezhan HealthCare Co Ltd
SHE:000813 |
Drug Manufacturers - Specialty & Generic | 0.09% |
|
Chongqing Pharscin Pharmaceutical Co Ltd
SHE:002907 |
Drug Manufacturers - Specialty & Generic | 14.54% |
Lupin Limited Asset Resilience Ratio by Year (2012–2026)
Lupin Limited asset resilience ratio by year from 2012 to 2026. The table below shows the annual Asset Resilience Ratio data for Lupin Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2026-03-31 | 9.32% | Rs35.77 Billion ≈ $386.85 Million |
Rs383.65 Billion ≈ $4.15 Billion |
+4.37pp |
| 2025-03-31 | 4.95% | Rs14.46 Billion ≈ $156.40 Million |
Rs292.05 Billion ≈ $3.16 Billion |
+0.82pp |
| 2024-03-31 | 4.13% | Rs9.91 Billion ≈ $107.17 Million |
Rs239.97 Billion ≈ $2.60 Billion |
+1.19pp |
| 2023-03-31 | 2.94% | Rs6.74 Billion ≈ $72.92 Million |
Rs229.56 Billion ≈ $2.48 Billion |
-1.71pp |
| 2022-03-31 | 4.65% | Rs10.14 Billion ≈ $109.70 Million |
Rs218.21 Billion ≈ $2.36 Billion |
-5.77pp |
| 2021-03-31 | 10.42% | Rs24.59 Billion ≈ $265.98 Million |
Rs236.10 Billion ≈ $2.55 Billion |
+0.64pp |
| 2020-03-31 | 9.78% | Rs24.43 Billion ≈ $264.16 Million |
Rs249.84 Billion ≈ $2.70 Billion |
+2.08pp |
| 2019-03-31 | 7.69% | Rs21.51 Billion ≈ $232.57 Million |
Rs279.49 Billion ≈ $3.02 Billion |
+6.50pp |
| 2018-03-31 | 1.20% | Rs3.15 Billion ≈ $34.03 Million |
Rs263.05 Billion ≈ $2.84 Billion |
-6.92pp |
| 2017-03-31 | 8.11% | Rs21.59 Billion ≈ $233.50 Million |
Rs266.07 Billion ≈ $2.88 Billion |
+8.06pp |
| 2016-03-31 | 0.05% | Rs120.20 Million ≈ $1.30 Million |
Rs226.25 Billion ≈ $2.45 Billion |
-12.55pp |
| 2015-03-31 | 12.60% | Rs16.56 Billion ≈ $179.08 Million |
Rs131.38 Billion ≈ $1.42 Billion |
+10.88pp |
| 2014-03-31 | 1.73% | Rs1.76 Billion ≈ $19.08 Million |
Rs102.06 Billion ≈ $1.10 Billion |
+1.73pp |
| 2012-03-31 | 0.00% | Rs1.50 Million ≈ $16.22K |
Rs79.82 Billion ≈ $863.25 Million |
-- |
About Lupin Limited
Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India, the United States, and internationally. The company operates in two segments: Pharmaceuticals and Others. It produces, develops, and markets various branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs). The company also offers products in the therapeutic … Read more